Relationship Between Protein Oxidation Markers and Oxidative Stress Biomarkers by Silvia Clara Kivatinitz
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
13 
Relationship Between Protein Oxidation 
Markers and Oxidative Stress Biomarkers 
Silvia Clara Kivatinitz 
Dept. Química Biológica, Fac. Ciencias Químicas,  
Universidad Nacional de Córdoba, Ciquibic-Conicet, 
Argentina 
1. Introduction 
There is a general agreement (belief) that lipids are the pivotal element in inflammatory 
disease. One of the most studied topics is the connection between lipid oxidation and 
cardiovascular disease. In a very recent review, the introductory paragraphs states, after 
resuming the elements of the inflammatory response starting with stimulated endothelium 
displaying adhesive molecules for circulating leucocytes, lipid oxidation products formed 
by virtually every vascular cell type participate in orchestrating these processes and the 
inflammatory process is actively limited by activation of a resolution phase, often via 
generation of structurally specific oxidized lipids whose function is to orchestrate resolution 
of inflammation (McIntyre & Hazen 2010).  
Most of the knowledge involving lipid oxidation comes from “in vitro” studies and on 
supplementation trials with antioxidants like vitamins and anti-inflammatory drugs. Vitamins 
E and C are considered dietary antioxidants although mostly ex vivo measurements of lipid 
peroxidation have been performed (Hillstrom et al. 2003; Heinecke 2001). Quantifying “in 
vivo” lipid oxidation is not easy and several biomarkers of lipid peroxidation has been used 
like F2-isoprostanes, considered the most accurate way to measure oxidative stress “in vivo”, 
and as a risk factor for atherosclerosis and other diseases (Lawson et al. 1999). 
The secondary products of lipid peroxidation (LPO) the reactive carbonyl compounds, modify 
biologically essential molecules such as proteins and DNA bases (Yuan et al. 2006). Thus lipid 
oxidation processes in biological tissues may be more complicated since they contain a 
plethora of carbohydrates, proteins and lipids forming a complex matrix. In tissues, lipid 
oxidation can cause protein oxidation due to close interactions between lipids and proteins. 
LPO “in vivo” has been implicated as the underlying mechanisms in numerous disorders and 
diseases such as cardiovascular diseases, cancer, neurological disorders, and aging.  
Thus, when oxidative stress biomarkers are evaluated protein oxidation deserves 
consideration. 
2. Protein oxidation  
In the next paragraphs I will analyze several works about protein oxidation “in vitro” 
(incubation in test tubes, cells systems, perfusion, foods) and “in vivo” (disease epidemiology 
and animal models mostly) with the intention of stressing similarities and differences between 
them. The next table is an outline of the literature reviewed in points 2.1 and 2.2. 
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Protein oxidation 
“in vitro” 
Characteristis of the 
model employed 
Main observation 
(Batthyány et al. 
2000) 
Copper binding to 
apolipoprotein B-100 is 
necessary for oxidation 
Formation of protein-tryptophanyl 
radicals 
(Yang et al. 1997) LDL treated with HOCL Selective process of modification of 
apoB-100 by HOCL 
(Hedrick et al. 
2000) 
Incubation of HDL under 
hyperglycaemic conditions  
Changes in HDL caused by 
hyperglycaemia contribute to  
accelerated atherosclerosis 
(Chantepie et al. 
2009) 
HDL treated with HOCL Small, dense HDL less susceptible to 
oxidative modification 
(Sigalov & Stern 
2001) 
Reconstituted HDL containing 
oxidized apo A-I  
Destabilization of the oxidized protein 
to denaturation  
(Chen et al. 2007) Polyphenolics  in the Cu(2+)-
induced generation of 
conjugated dienes of LDL 
Polyphenolics  reduce oxidation  of 
apoB-100 
(Arai & Nakamura 
2004) 
VLDL oxidation induced by 
peroxyl radicals and 
peroxynitrite 
Ascorbic acid protects apolipoprotein E 
of oxidation 
(Jedidi et al. 2003) LDL oxidation was mediated 
by water gamma radiolysis 
(*)OH initiate oxidation leading to apob 
carbonylation in presence of 
aminoguanidine 
(Roland et al. 
2001) 
LDL and Cu(2+) Flavonoids myricetin, quercetin, and 
catechin decreased copper binding to 
LDL 
(Patterson et al. 
2003) 
LDL, human serum 
ultrafiltrate of Mr below 500 
and hydroperoxide or Cu(2+) 
Low Cu(2+) inhibit tocopherol induced 
oxidation in LDL, promote breakdown 
of lipid hydroperoxides into radicals 
(Makedou et al. 
2009) 
Copper-induced Low-density 
lipoprotein (LDL) oxidizability
Progeny with a positive family history 
for  hyperlipidemia have increased LDL 
susceptibility to oxidation 
(Hockerstedt et al. 
2004) 
Copper-induced oxidation of 
purified HDL 
LCAT causes estradiol esterification and 
thus provide antioxidant protection to 
HDL 
(Moreno & Fuster 
2004) 
LDL oxidation susceptibility to 
Cu(2+) 
Apolipoprotein E polymorphism 
partially explain differences in 
individual responses to diet 
(Popa et al. 2009) HDL ability to inhibit copper-
induced oxidation of low-
density lipoprotein (LDL) 
Infliximab has beneficial effects on 
lipids through changes in HDL 
antioxidative capacity 
(Deakin et al. 
2002) 
Transfection of CHO cells, did 
not co-secretate apo A-I and 
lipids leading to formation of 
Accumulation of PON1 in cell mem-
brane was not influenced by the ability 
of the cell to co-secrete of apoA-I 
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HDL-like complexes 
(Allen & Jandeleit-
Dahm 2005) 
Review Recognised metabolic abnormalities 
upregulation of advanced glycation 
endproducts, renin-angiotensin system, 
oxidative stress associated with diabetes 
(Shao et al. 2010) Revision Biochemical studies implicated tyrosine 
chlorination and methionine 
oxygenation in the loss of ABCA1 and 
LCAT activity by oxidized apoA-I 
(Obama et al. 
2007) 
Copper-induced oxLDL Histidine residue modified by 4-
hydroxynonenal, a major lipid 
peroxidation product, oxidized 
histidine and tryptophan residues 
(Suc et al. 2003) Tyrosylation of high-density 
lipoprotein 
HDLT competes with oxidized and 
acetylated LDL, ligands of scavenger 
receptor class B type I/II 
(Zarev et al. 2002) LDL oxidation induced in vitro 
by copper and *OH/O*(2)(-) 
free radicals generated by 
gamma-radiolysis 
Apolipoprotein B carbonylated 
fragmentation not detected during the 
lag phase of copper-oxidized LDL but 
detected during the propagation phase 
(Edelstein et al. 
2001) 
Oxidation of LDL by Cu(2)+ or 
the combined phospholipase 
A2 and lipoxygenase system 
Apo[a] but not apoB-100 resists 
oxidative fragmentation,  apoB-100 can 
be degraded by enzymes and oxidation 
(Gao et al. 2008) Copper and hypochlorite 
(prefer´-entially oxidize lipids 
or proteins, respectively) 
oxidation of HDL
Mild oxidation favor HDL remodeling 
due to diminished apolipoprotein 
affinity for lipids due to oxidation of 
methionine and aromatic residues 
(Gomes et al. 2002) Beta 2-Glycoprotein I (beta 2 
GPI), macrophage uptake of 
particles with 
phosphatidylserine containing 
surfaces, and unilamellar 
vesicles  
Particle uptake in the presence of beta 2 
GPI is coupled to an inhibition of 
reactive species production by liver 
macrophagest 
(Jolivalt et al. 2000) Myeloperoxidase oxidative 
system 
Oxidation of apo E decreases its 
incorporation into phospholipid discs 
by approximately 50%
(Van Antwerpen 
et al. 2006; Van 
Antwerpen et al. 
2005) 
LDL oxidation by 
myeloperoxidase 
Thiol-containing molecules such as 
glutathione, captopril, and N-
acetylcysteine (NAC) and its lysinate 
salt (NAL) 
Protein oxidation
“in vivo” 
Characteristis of the model 
employed
Main observation 
(Hershfield et al. 
2010) 
Erythrocytes Urate is not a major factor controlling 
oxidative stress in vivo 
(Janatuinen et al. Young adults with Type 1 Pravastatin decreased LDL oxidation; 
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2004) Diabetes without improvement in myocardial 
perfusion 
(Zhang et al. 2002) A model of inflammation 
(peritonitis) with MPO 
knockout mice (MPO−/−) 
MPO-dependent formation of  NO-
derived oxidants, and not tyrosyl 
radical, serve as a preferred pathway 
for initiating lipid peroxidation. 
(Seshadri et al. 
2002) 
Transfected HepG2 Insulin functions as a bidirectional, 
condition-dependent regulator of 
hepatic cell Ceruloplasmin expression, 
reflecting its dual roles in inflammation  
(Yoshida & Kisugi 
2010) 
Review Several pathways are involved in the 
promotion of LDL oxidation in vitro 
and in vivo, but the physiologically 
relevant mechanisms of LDL oxidation 
are still imperfectly understood 
(Allen & Jandeleit-
Dahm 2005) 
Review Glycation endproducts, renin-
angiotensin system, oxidative stress and 
increased expression of growth factors 
and cytokines have been observed in 
the setting of diabetes 
(Erciyas et al. 
2004) 
Children with type 1 diabetes 
mellitus 
Relationship between the lipid profile 
and oxidative stress 
(Candore et al. 
2010) 
Review Cholesterol, oxidative stress and 
related therapeutic possibilities, i.e., 
nonsteroidal antiinflammatory drugs, 
immunotherapy, diet, and curcumin 
(Bassett & 
Montine 2003) 
Review ApoE isoforms may specifically 
influence the cellular distribution of 
lipid peroxidation products in brain 
(Shao et al. 2008) Incubation of oxidized HDL 
and LCAT 
Oxidation of a single Met in apoa-I in 
impaired LCAT activation, a critical 
early step in reverse cholesterol transport 
(Haberland et al. 
1988) 
Watanabe heritable 
hyperlipidemic rabbits 
Presence of protein modified by 
malondialdehyde which colocalizes 
with the extracellular deposition of 
apolipoprotein B-100 
(Palinski et al. 
1989) 
Rabbit and human Autoantibodies against 
malondialdehyde-LDL (titers from 512 
to greater than 4096) can be 
demonstrated in sera 
(Artola et al. 1997) Hypercholesterolemic chickens HDL from treated animals was more 
peroxidized, had higher amount of 
oligomeric apoA-I, than that of control 
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animals 
(Ónody et al. 2003) Rat experimental 
hyperlipidemia 
Induced hyperlipidemia leads to an 
increase in cardiac ONOO− formation 
and a decrease of NO and deterioration 
of cardiac performance 
(Ueno et al. 2002) Diabetic Akita mice Hyperglycemia induced oxidative stress 
(Wiggin et al. 
2008) 
Streptozotocin-treated DBA/2J 
mice 
Rosiglitazone treatment did not affect 
hyperglycemia but did reduce oxidative 
stress and prevented the development 
of thermal hypoalgesia 
Table 1. Bibliography reviewed about protein oxidation “in vitro” and “in vivo”. 
2.1 “In vitro” protein oxidation 
The oxidation of lipoproteins has been studied in diverse “in vitro” systems using several 
experimental approaches i.e.; cupric ion (Batthyány et al. 2000), HOCl (Yang et al. 1997) or 
glycation mimicking diabetic conditions (Hedrick et al. 2000). More complex systems using 
“in vitro” cells systems had also been used. 
Protein becomes modified during oxidation, resulting in a change in the protein conformation 
and degradation of amino acids, e.g., tryptophan and tyrosine (Batthyány et al. 2000), or amine 
groups (Chantepie et al. 2009) or methionine (Sigalov & Stern 2001). Different subclasses of 
lipoproteins, which differ in size or charge, have been shown to display different susceptibility 
to “in vitro” oxidation (Chantepie et al. 2009; Chen et al. 2007). Both apolipoprotein-B and 
apolipoprotein-A has been subjected to several oxidation processes and structural, chemical 
and biological functions alterations reported. Also, the effect of several antioxidants such as 
vitamins (Arai & Nakamura 2004), polyphenolic compounds (Chen et al. 2007) and inhibitors 
of glycation (Jedidi et al. 2003) has been reported. 
Copper has been often used to oxidize LDL (low density lipoprotein) in experiments “in 
vitro” and was proposed as a candidate for oxidizing LDL in atherosclerotic lesions. Copper 
ions bind to LDL being the copper-binding capacity progressively and markedly higher 
when LDL is increasingly oxidized. It was assessed that the flavonoids myricetin, quercetin, 
and catechin (but not epicatechin, kaempferol, or morin), at concentrations equimolar to the 
copper present significantly decreased copper binding to LDL (Roland, Patterson, & Leake 
2001). Later, the same group proposed uric acid as both antioxidant and prooxidant for LDL. 
They suggested that reduction of Cu+2 to Cu+ was behind the effects observed since the 
decreased concentration of Cu+2 would inhibit tocopherol-mediated peroxidation in native 
LDL, and the generation of Cu+ would promote the rapid breakdown of lipid 
hydroperoxides in mildly oxidized LDL into lipid radicals (Patterson, Horsley, & Leake 
2003).  These, other “in vitro” observations and the high plasma urate concentration, related 
to loss of urate oxidase in evolution, are postulated to protect humans from oxidative injury. 
This hypothesis has broad clinical relevance, but support rests largely on “in vitro” data and 
epidemiologic associations. Recently, “in vivo” evidence seems to deny such a physiological 
or pathological role. Therapy with infusion of PEGylated recombinant porcine urate oxidase 
generates H2O2 while depleting urate. Oxidative stress was monitored with F2-Isoprostanes 
(F2-IsoPs) and protein carbonyls (PC), products of arachidonic acid and protein oxidation, in 
plasma of 26 refractory gout patients receiving infusions of the enzyme. At baseline, urate 
was markedly elevated in all patients, and plasma F2-IsoP concentration was elevated in 
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most. Treatment rapidly lowered urate in all patients, but did not correlate with 
isoprostanes or protein carbonyls. The authors conclude that urate is not a major factor 
controlling oxidative stress “in vivo” (Hershfield et al. 2010). 
Another interesting aspect of research is the one that deals with the susceptibility of 
lipoprotein taken from atherosclerotic lesions or from patients receiving pharmacological 
treatment with anti-inflammatory or hypolipemic drug therapy. For example, it has been 
found that descendants with a positive family history for cardiovascular disease (CVD) or 
hyperlipidemia have an atherogenic lipid profile and increased LDL susceptibility to 
oxidation (Makedou et al. 2009). 
Also it has been suggested that endogenous estrogens protect against atherosclerosis by 
inhibition of lipoprotein oxidation. To act as antioxidants, estrogens need to be converted to 
lipophilic estrogen fatty acyl esters in a reaction catalyzed by lecithin: cholesterol 
acyltransferase (LCAT) (Hockerstedt, Jauhiainen, & Tikkanen 2004). Another hint linking 
LDL oxidative status and disease is the association between apolipoprotein E gene promoter 
polymorphism (–219G→T) has been with increased risk of myocardial infarction, premature 
coronary artery disease, and decreased plasma apolipoprotein E concentrations. The 
presence of the T allele in the apolipoproteinE –219G→T polymorphism increases the 
susceptibility of plasma LDL to oxidative modifications and enhances the response of 
apolipoprotein B and LDL cholesterol to the presence of saturated fat in the diet of healthy 
men (Moreno et al. 2004). 
In Rheumatoid Arthritis (RA) patients, another disease of inflammatory etiology, effects of 
tumor necrosis factor (TNF) on the antioxidative capacity of HDL has been investigated and 
it was observed that has beneficial effects on lipids through changes in HDL (high density 
lipoprotein) antioxidative capacity, which might be clinically relevant and contribute to the 
reported protective effect of anti-TNF on cardiovascular morbidity in Rheumatoid Arthritis 
(Popa et al. 2009). This observation emphasizes the importance of HDL antiatherogenic 
capacity for cardiovascular risk in chronic inflammatory conditions. 
Lipoproteins are very heterogeneous particles that contain several active enzymes and 
interact with other circulating proteins. Several of the these intrinsic or interacting enzymes 
have oxidative or antioxidative functions, e. g., paraoxonase-1 (Deakin et al. 2002), renin-
angiotensin system (Allen & Jandeleit-Dahm 2005), or myeloperoxidase (Shao et al. 2010). 
Most interestingly, changes in the interaction between apolipoprotein and shell lipids has 
been shown to occur when HDL or LDL were subject to oxidation “in vitro” (Obama et al. 
2007; Suc et al. 2003; Zarev et al. 2002). These changes in lipid protein interaction seem to be 
of importance for the biological function and receptor binding (Edelstein et al. 2001; Gao, 
Jayaraman, & Gursky 2008; Gomes et al. 2002; Hedrick et al. 2000). One example of the 
alteration in lipid-protein interaction was obtained using the myeloperoxidase (MPO) 
oxidative system. The researchers reported that oxidation of the three recombinant 
apolipoprotein E isoforms was differential, with apolipoprotein E4 being more susceptible 
than apolipoprotein E3, which in turn is much more susceptible than apolipoprotein E2 and 
that oxidation of apolipoprotein E decreases its incorporation into phospholipid discs 
(Jolivalt et al. 2000). LDL was also modified by MPO “in vitro” and by thiol-containing 
molecules as glutathione, captopril, and N-acetylcysteine has been shown to act as 
antioxidants (Van Antwerpen et al. 2005; Van Antwerpen et al. 2006). The ability of MPO to 
initiate lipid peroxidation “in vivo” and its role in generating bioactive eicosanoids during 
inflammation has been explored using a model of inflammation (peritonitis) with MPO 
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knockout mice (MPO−/−). Peritonitis-triggered formation of F2-isoprostanes, a marker of 
oxidant stress “in vivo” and was reduced by 85% in the MPO−/− mice. Parallel analyses of 
peritoneal lavage proteins for protein dityrosine and nitrotyrosine, molecular markers for 
oxidative modification by tyrosyl radical and ⋅NO2, respectively, revealed marked 
reductions in the content of nitrotyrosine, but not dityrosine, in MPO−/−samples. Thus, 
MPO serves as a major enzymatic catalyst of lipid peroxidation at sites of inflammation. 
Moreover, MPO-dependent formation of ⋅NO- derived oxidants, and not tyrosyl radical, 
appears to serve as a preferred pathway for initiating lipid peroxidation and promoting 
oxidant stress “in vivo” (Zhang et al. 2002). These findings indicate that the proposed role of 
MPO in dityrosine cross-linking were erroneous and suggest that alternative mechanisms 
participate in dityrosine formation in this model, such as protein-bound redox active 
transition metal ions, and ceruloplasmin (Seshadri, Fox, & Mukhopadhyay 2002). 
2.2 “In vivo” protein oxidation 
There are many reports that relate diseases caused by oxidative imbalance with 
characteristic features of oxidized protein “in vivo”. Many lines of evidence suggest that 
oxidized LDL is implicated in the pathogenesis of atherosclerotic vascular diseases (Yoshida 
& Kisugi 2010), in diabetes (Allen & Jandeleit-Dahm 2005; Erciyas et al. 2004), Alzheimer 
(Candore et al. 2010; Bassett & Montine 2003) . 
Recently, it has been demonstrated that HDL isolated from patients with established 
cardiovascular disease contains elevated levels of 3-chlorotyrosine and 3-nitrotyrosine, two 
characteristic products of MPO. When apolipoprotein A-I, the major HDL protein, was 
oxidized by MPO, its ability to promote cellular cholesterol was impaired. Moreover, 
oxidized apolipoprotein A-I was unable to activate LCAT, which rapidly converts free 
cholesterol to cholesteryl ester, a critical step in HDL maturation (Shao et al. 2010). 
Biochemical studies implicated tyrosine chlorination and methionine oxygenation in the loss 
of ability to promote cellular cholesterol efflux and LCAT activity by oxidized 
apolipoproteinA-I (Shao et al. 2008).  
In animal studies, the existence of oxidized apolipoproteins has been described under 
several experimental models, i.e. in Watanabe heritable hyperlipidemic rabbits the 
occurrence of malondialdehyde-LDL and of autoantibodies against malondialdehyde-LDL 
has been reported (Haberland, Fong, & Cheng 1988; Palinski et al. 1989). HDL from 
hypercholesterolemic chickens bear peroxidized oligomeric apolipoprotein A-I consequence 
of “in vivo” oxidation process (Artola et al. 1997). Interestingly, the oligomerization of 
apolipoprotein A-I implied dityrosine crosslink formation.   
It was found that high-cholesterol diet increases formation of a potential marker of cardiac 
ONOO−, dityrosine in the perfusate, demonstrating that hyperlipidemia increases ONOO− 
formation in the heart (Ónody et al. 2003). In contrast to dityrosine, perfusate nitrotyrosine 
was not statistically significantly increased in the study. This can be explained by results 
showing that at relatively low level of ONOO−, nitrotyrosine formation is suppressed in 
favor of dityrosine (Ónody et al. 2003). 
Both the levels of dityrosine and Nε-(hexanonyl)lysine were significantly elevated in the 
kidneys of diabetic Akita mice compared with the control mice without any accumulation of 
thiobarbituric acid reactive substances and 4-hydroxy-2-nonenal-modified protein (Ueno et 
al. 2002). These findings are consistent with previous works showing that diabetes increases 
oxidized lipids and protein. In another model of diabetic mice, increased levels of dityrosine 
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were found in the nerve of treated mice that had developed neuropathy respect to the 
control mice (Wiggin et al. 2008). 
In one study, LDL oxidation and myocardial perfusion were measured in 
normocholesterolemic patients with type 1 diabetes before and after 4-month treatment with 
pravastatin or placebo. Pravastatin decreased LDL oxidation without improvement in 
myocardial perfusion reserve measured by positron emission tomography (Janatuinen et al. 
2004).  
2.2.1 Pharmacological treatments with antioxidant effects 
The pathogenesis of chronic inflammatory diseases is regulated by modulation of the 
expression of redox-sensitive inflammatory genes including adhesion molecules, chemokines, 
cytokines and several receptors (Khatami 2009). The inflammation of vasculature produces 
reactive oxygen species (ROS) released both extracellularly from activated leukocytes as well 
as intracellularly in cells involved in the inflammatory reaction. ROS can be toxic and not only 
cause damage to biomolecules (DNA, proteins, lipids) but have been recognized as important 
intracellular signaling mediators (Nordberg & Arnér 2001).  
Besides vasculature system, free radicals are constantly produced in the brain “in vivo”. 
Because of its high ATP demand, the brain consumes oxygen rapidly, and is thus 
susceptible to interference with mitochondrial function, which can in turn lead to increased 
superoxide radical formation (Zorov et al. 2006). Free radicals in central nervous system 
arise by the leakage of electrons from the mitochondrial electron transport chain to generate 
superoxide radical  and are generated for precise purposes, such as the role of nitric oxide in 
neurotransmission and the production of superoxide radical by activated microglia 
(Breckwoldt et al. 2008).  
Increased levels of oxidative damage to DNA, lipids and proteins have been detected by a 
range of assays in post-mortem tissues from patients with Parkinson’s disease, Alzheimer’s 
disease and amyotrophic lateral sclerosis, and at least some of these changes may occur 
early in disease progression (Ursini et al. 2002; Paula-Lima et al. 2009). The accumulation 
and precipitation of proteins that occur in these diseases may be aggravated by oxidative 
damage, and may in turn cause more oxidative damage by interfering with the function of 
the proteasome (Cook & Petrucelli 2009). Indeed, it has been shown that proteasomal 
inhibition increases levels of oxidative damage to proteins and to other biomolecules. 
Hence, there are many attempts to develop antioxidants that can cross the blood-brain 
barrier and decrease oxidative damage (Halliwell 2007) and of biopharmaceuticals that can 
counteract protein oxidation and precipitation-aggregation (Wang 2005). 
Aggregation of proteins is a common feature triggered by protein oxidation and it has been 
found “in vitro and “in vivo” being carbonylation a common feature (Mirzaei & Regnier 
2008). Aggregation is manifest in globular proteins, because under stress conditions or 
proteolysis nonnative conformations can be adopted. Although it seems that most proteins 
are able to form aggregates when expressed at high concentrations “in vitro”, they differ 
substantially in their intrinsic propensity to do so “in vivo”. The major contributors to 
aggregation propensity have been identified as hydrophobicity, net charge and propensity 
to form beta-sheet instead of alpha-helical structures (Tartaglia & Caflisch 2007).  
There is a large body of evidence demonstrating a role for ROS and oxidant stress in the 
pathogenesis of RA. Both preclinical and clinical studies have demonstrated relationship 
between oxidative stress biomarkers with disease progression  and the potential beneficial 
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effects of antioxidant supplementation or therapy (Uchida 2008). Although a complete 
understanding of how oxidative stress participates in the pathogenesis of RA is lacking, 
there is evidence demonstrating that expression of several inflammatory genes that 
participate in RA  is regulated by redox-sensitive signaling pathways (Filippin et al. 2008). 
Other cells that have an important role in inflammation are lymphocytes. Distinct types of 
lymphocytes have divergent effects of inflammation. For example; Tr1-type regulatory 
immune response cells (CD4CD25 T-cells) reduces the development of experimental 
atherosclerosis, while the activation of T-lymphocytes contributes importantly to 
atherogenesis (Mallat et al. 2003). In human atheroma, CD4-positive cells, the major T-cell 
population, appear to promote atherosclerosis through elaboration of proinflammatory 
cytokines, such as interferon (IFN), tumor necrosis factors (TNFs), and interleukin (IL)-2 
(Zhou et al. 2000). In fact, patients with atherosclerosis and acute coronary syndromes 
exhibit T-cell activation and increased IFN serum levels (Liuzzo et al. 1999) and there is 
evidence that fibrates, drugs that are PPAR agonists, are anti-inflammatory mediators 
because they limit inflammatory cytokine expression of T lymphocytes (Marx et al. 2002). 
Statins are currently the medical treatment of choice for hypercholesterolemia. In addition to 
attaining a decrease in serum cholesterol levels, statin therapy seems to promote other 
effects that are independent of changes in serum cholesterol. These ‘‘pleiotropic’’ effects 
include attenuation of vascular inflammation, improved endothelial cell function, 
stabilization of atherosclerotic plaque, decreased vascular smooth muscle cell migration and 
proliferation, and inhibition of platelet aggregation (Sadowitz et al. 2010) and increase the 
synthesis of apolipoprotein A-I and HDL biogenesis in the liver (Yamashita et al. 2010). 
Interestingly, statin therapy in dyslipidemic type 2 diabetic patients plays a protective role 
on the lipid and protein oxidative damage (Manfredini et al. 2010). We have tested the effect 
of a statin (atorvastatin) and of a fibrate (fenofibrate) on the activation of T lymphocytes in 
culture by an unspecific mitogen (concanavalin A). It was noted that upon activation with 
concanavalin A T-cells expressing IL-2 receptor (CD25, marker of activation) are augmented 
and that VLDL (very low density lipoprotein) inhibit the proportion of CD25+ CD4+ cells 
after 48 h of co-culturing. When lymphocytes were cultured with VLDL plus Atorvastatin 
CD25CD4 positive cells increased respect to cell culture with VLDL alone, suggesting that 
another anti-inflammatory effect of the statin (Forcato et al. 2007). In another study, it has 
been shown that the combined treatment of pravastatin with irbesartan reduced sPLA2-IIA-
activity, sPLA2-IIA-protein concentration, and oxidized LDL in patients with CAD 
suggesting a novel anti-atherogenic effect by combining AT1-receptor blockade with statin 
treatment (Divchev et al. 2008). 
Human hepatocyte cells in different cell cycle phases (G1 and G2/M) were analyzed using 
flow citometry techniques for VLDL receptor (VLDLR+). VLDLR+ cells belonged equally to 
cells in the quiescent and in the synthesis or mitosis phase of the cell cycle. Challenging 
them with lipopolysaccharide an increase in the percentage of VLDLR+ cells was produced. 
Gemfibrozil treatment decreased the number of resting VLDLR+ hepatocytes but increased 
significantly (more than twice) the number of VLDLR+ hepatocytes in phase G2/M (Forcato 
et al. 2007). These observations could explain why fenofibrate is particularly effective for 
reducing postprandial VLDL and LDL particle concentrations, and the increased oxidative 
stress and inflammatory response that occurs after a fatty meal (Rosenson 2008). 
It is interesting to note that metabolites of statins and fenofibrate, but not the parent drugs, 
had been implied in protecting lipoproteins from oxidation “in vitro” suggesting that the 
antioxidant effects will be relevant “in vivo” (Aviram et al. 1998). 
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2.3 Oxidation of proteins in tissues and fluids, where there are good and bad 
neighbors 
In this section I pretend to discuss some new insights about reactions that occur only in 
complex milieu as the appearance of acrylamide (Stadler et al. 2004), the antioxidant activity 
of Maillard products (Yilmaz & Toledo 2005) and discuss that some antioxidants produces 
oxidative modifications of proteins. Polyphenolic compounds have powerful antioxidant 
effects “in vitro”  in many test systems, but can act as pro-oxidants in some others (Halliwell 
2007). And it has been reported that tea catechins contribute to the formation of protein 
carbonyl in human  serum albumin (HSA) (Ishii et al. 2010). 
2.3.1 Acrylamide from food is absorbed in humans  
The heating of free amino acids, in particular asparagine, and sugars during food processing 
(120–180°C) results in the formation of acrylamide (Stadler et al. 2002). Most of the 
acrylamide ingested with food (i.e. fried potatoes) is absorbed in humans. Acrylamide and 
its metabolite glycidamide have the capability to bind covalently to the −SH and −NH2 
groups of proteins and nucleic acid nitrogens. Although both acrylamide and glycidamide 
DNA adducts are formed “in vitro”, only glycidamide adducts have been found after the 
administration of acrylamide or glycidamide “in vivo”(Gamboa da Costa et al. 2003). 
Acrylamide and glycidamide adducts to the NH2-terminal valine of human hemoglobin are 
used as convenient biomarkers for external acrylamide and/or internal glycidamide 
exposure. Acrylamide and glycidamide are also able to form glutathione conjugates that 
have been found in human urine, these metabolites have been proposed as biomarkers for 
acrylamide and glycidamide exposure (Fuhr et al. 2006). It is important to stress that there is 
no report of acrylamide formation in humans. 
2.3.2 Antioxidant activity of Maillard products 
Nonenzymatic glycation of free amino groups on proteins and amino acids is a biochemical 
reaction known as the “Maillard reaction.” It has been proposed that this is an evolutionary 
pathway for labeling of senescent cellular proteins for their recognition and ultimate 
degradation. The two traditional factors found to modulate the early glycation of proteins 
are the concentration of glucose and half life of the protein, so in both major forms of 
diabetes, persistent hyperglycemia and oxidative stress act to increase the formation of 
advanced glycation end products (Reddy et al. 2009).  But evidences in the literature have 
documented an increased glycated protein levels in some non-diabetic pathological states. 
Recently it has been hypothesized that oxidative stress either via increasing reactive oxygen 
species or by depleting the antioxidants may modulate the genesis of early glycated proteins 
“in vivo”. This hypothesis was sustained by the observations that a common denominator in 
all non-diabetic pathological conditions is oxidative stress and that malondialdehyde, 
reduced glutathione, vitamin C, vitamin E and drugs with antioxidant properties mitigate 
the process of protein glycation (Selvaraj et al. 2008). Maillard reactions occurring “in vivo” 
are associated with the chronic complications of diabetes mellitus and aging and age-related 
diseases by increases in oxidative chemical modification of lipids, DNA, and proteins. In 
particular, long-lived proteins such as lens, crystallines, collagens, and hemoglobin may 
react with reducing sugars to form advanced glycation end products and are biomarkers for 
detecting oxidative stress produced during Maillard reaction (Osawa & Kato 2005). 
The relationship between yin-yang and anti-oxidation-oxidation (Ou et al. 2003) seems also 
valid for Maillard reaction products since antioxidant activity of Maillard reaction products 
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has been demonstrated “in vitro” in foods. The existence of this relationship “in vivo” will 
be a subject of research in the future since a few studies have been reported exploring the 
antioxidant capacity of Maillard reaction products using “in vivo” systems (Chen & Kitts 
2008). 
2.3.3 Oxidant activity of antioxidants  
Recent studies have reported that various polyphenolic compounds, including catechins, 
cause protein carbonyl formation in proteins via their pro-oxidant actions. The oxidation 
stability and binding affinity of catechins with proteins and with fatty acids bound to 
protein are responsible for the formation of protein carbonyl (Dufour et al. 2007). 
Polyphenol binding altered BSA conformation with a major reduction of alpha-helix and an 
increase in beta-sheet and turn structures, indicating a partial protein unfolding (Bourassa et 
al. 2007) that could increase BSA oxidation susceptibility. Some authors have claimed that 
antioxidants can stimulate oxidative damage “in vivo”, especially ascorbate, alleged in 
several studies to increase oxidative DNA damage (Perron et al. 2011). 
2.3.4 Aggregation and proteolysis are defense or repair mechanisms?  
Moderately oxidized soluble cell proteins are selectively and rapidly degraded by the 20S 
proteasome, while harshly oxidized, aggregated, and crosslinked proteins are poor 
substrates and actually inhibit the proteasome (Davies & Shringarpure 2006). During aging, 
and in many age-related diseases/disorders, the proteasome is progressively inhibited by 
binding more protein aggregates. It has been postulated that an increase in the generation of 
reactive oxygen species as well as a decline in proteasome activity, results in the progressive 
accumulation of oxidatively damaged protein aggregates that eventually contribute to 
cellular dysfunction and senescence in senesce and disease (Davies & Shringarpure 2006). 
Small endogenous peptides, such as peptide hormones and signaling peptides, have strong 
effects on human. This has prompted an increasing interest from academia and food 
industries where it is reasoned that certain dietary peptides could also be potentially used as 
bioactive ingredients in functional foods. Dietary proteins have sequences of peptides, 
partially similar to those found in endogenous peptides, with hormonal or neuronal 
functions, and it has been proposed to exert physiological effects by acting either 
agonistically or antagonistically on the same targets as their endogenous counterparts 
(Ahlman & Nilsson 2001). Scientists are currently exploring use of protein sources such as 
mammalian and fish meat, soybeans, chickpeas, almonds, etc. for production of bioactive 
peptides with different biological activities (Minkiewicz et al. 2011). Bioactive peptides can 
reduce free radicals and have antioxidant activity (Sarmadi & Ismail 2010).  
During protein oxidation aggregation and proteolysis occur simultaneaously, so it can be 
presumed that the balance between protein aggregation and antioxidant peptide generation 
is important in modulating inflammation “in vivo”. 
2.4 Dityrosine and other markers of protein oxidative modification “in vivo” 
Most of the oxidative modifications that occurs “in vivo” and “in vitro” are susceptible of 
reversion and thus it is necessary to discern stable markers (Davies et al. 1999). Dityrosine 
bound formation and protein polymerization seems to be less prone to “in vivo” reduction 
or repair (Artola et al. 1997; Nagy et al. 2010). Also protein carbonyls could be a marker of 
endogenous oxidative stress (D'Aguanno et al. 2010), taking in account that this could be a 
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better marker than dityrosine, when the oxidative stimulus is radiant energy (ultraviolet 
light) (Scheidegger et al. 2010).  
3. Conclusion  
3.1 Is there a relationship between oxidized apolipoprotein and health status? 
Inflammation is associated with atherosclerosis. Human lipoproteins have been recognized 
to have proinflammatory or anti-inflammatory roles together with their receptors and the 
molecules involved in the interaction of lipoproteins with receptors. In example, it has been 
demonstrated that the inflammatory mediator IL-1ß disrupts cholesterol-mediated LDL 
receptor feedback regulation, permitting unregulated intracellular accumulation of 
unmodified LDL and causing foam cell formation. The authors suggest that this mechanism 
may contribute to the development of atherosclerosis in patients with chronic inflammation 
(Ruan et al. 2006).  
On the other hand, the anti-atherogenic properties of HDL can be beneficial in metabolic 
diseases associated with accelerated atherosclerosis. Indeed, metabolic syndrome and type 2 
diabetes are characterized by elevated cardiovascular risk and by low HDL-cholesterol 
(HDL-C) levels, but also by defective HDL function. Functional HDL deficiency is intimately 
associated with alterations in intravascular HDL metabolism and structure. Indeed, 
formation of HDL particles with attenuated antiatherogenic activity is mechanistically 
related to core lipid enrichment in triglycerides and cholesteryl ester depletion, altered 
apolipoprotein A-I conformation, replacement of apolipoprotein A-I by serum amyloid A, 
and covalent modification of HDL protein components by oxidation and glycation (Kontush 
& Chapman 2006, 2010). “In vivo” oxidation of apolipoprotein-I is equally consistent with 
the observation that HDL from hypercholesterolemic chickens contain higher amounts of 
oligomeric apolipoprotein-I and are more susceptible to “in vitro” oxidation than HDL from 
control animals (Artola et al. 1997). 
Fenofibrate is a PPAR-α agonist indicated for the treatment of hypertriglyceridemia and 
mixed dyslipidemia, lipid abnormalities commonly observed in patients at high risk of 
cardiovascular disease, including Type 2 diabetes and/or metabolic syndromes. Treatment 
with fenofibrate lowers triglycerides, raises HDL-cholesterol and decreases concentrations 
of small LDL-cholesterol particles and apolipoprotein B. Fenofibrate is effective for reducing 
postprandial VLDL and LDL particle concentrations that occurs after a fatty meal (Rosenson 
et al. 2007).  This decrease in VLDL could be related to the increase in VLDL receptor cause 
by  Gemfibrozil  in spleen mononuclear cells, in human hepatocyte cells (HepG2) and in a 
human acute monocytic leukemia cell line (THP-1) cultured with the fibrate (Forcato 2008). 
Fibrate also produced an accumulation of apolipoprotein A-I in HepG2 (Forcato 2008). Thus 
it is probable that fibrates have several concurrent beneficial effects on hyperlipemia and 
oxidative imbalance. 
The existence of oxidized lipids in pathological state is a common feature. Normal arteries 
contained similar levels of protein as atherosclerotic arteries, much less free cholesterol, and no 
detectable amounts of unoxidized or oxidized cholesteryl esters. It has been demonstrated the 
coexistence in human plaque of large amounts of oxidized cholesteryl esters with significant 
concentrations of ascorbate and vitamin E and that compared with healthy human arteries, 
advanced atherosclerotic plaques are not deficient in the antioxidant vitamins C and E, despite 
the occurrence of massive lipid oxidation (Suarna et al. 1995). On the contrary the removal of 
oxidized phospholipid in normal cells is the norm. Oxidized phospholipids within LDL can 
promote phagocyte recognition and engulfment, even when present at only a few molecules 
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per particle, by CD36, a prototypic member of the class B scavenger receptor family (Hazen 
2008). The removal of oxidized lipids associated to lipoproteins or to membranes seems to 
grant a low level in physiological conditions.  
3.2 Damaged proteins are biomarkers of oxidation imbalance 
Damaged proteins are recognized by the proteolytic machinery for degradation to their 
constitutive amino acids; however, this process can be inefficient as is evidenced by their 
accumulation. Deposits of aggregated, misfolded, and oxidized proteins accumulate 
normally over time in cells and tissues, especially in postmitotic cells of the brain and heart, 
and are often present in increased amounts in a range of age-related disorders, such as 
atherosclerosis, neurodegeneration, and cataractogenesis (Dunlop et al. 2009; Dunlop Ra Fau 
- Rodgers et al. 2002). 
Oxidatively modified proteins are usually considered degraded more or less exclusively by 
the proteasome system, although this would only apply to mildly oxidized proteins since 
substrates must be unfolded to enter the narrow catalytic chamber of the 20S core (Dunlop 
Ra Fau - Rodgers, Rodgers Kj Fau - Dean, & Dean 2002). 
Altogether, these studies show that protein oxidation products may serve as biomarkers for 
oxidative free radical damage. The intracellular accumulation of oxidized forms of proteins 
is a complex function of prooxidant-antioxidant activities and the concentrations and 
activities of the proteases that degrade the oxidized forms of proteins (Stadtman & Levine 
2000). However, measurements are performed in tissue or plasma that is invasively 
obtained samples. Therefore, future studies will have to be conducted to find techniques to 
determine these products in urine as well (de Zwart et al. 1999). 
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